Diffusion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DFFN)

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Diffusion Pharmaceuticals shares reverse split before market open on Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.06. View Diffusion Pharmaceuticals' Earnings History.

Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Diffusion Pharmaceuticals.

1 brokers have issued 12 month target prices for Diffusion Pharmaceuticals' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Diffusion Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 589.7% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.

Headlines about DFFN stock have trended very negative on Thursday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Diffusion Pharmaceuticals.

Diffusion Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 80,300 shares, a decrease of 19.9% from the August 30th total of 100,200 shares. Based on an average daily trading volume, of 65,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.8% of the shares of the stock are short sold. View Diffusion Pharmaceuticals' Current Options Chain.

Some companies that are related to Diffusion Pharmaceuticals include Acer Therapeutics (ACER), Adamis Pharmaceuticals (ADMP), Bio-Path (BPTH), Aptevo Therapeutics (APVO), Addex Therapeutics (ADDXF), Fibrocell Science (FCSC), DiaMedica Therapeutics (DMAC), Clearside Biomedical (CLSD), Akari Therapeutics (AKTX), Leap Therapeutics (LPTX), Alimera Sciences (ALIM), China SXT Pharmaceuticals (SXTC), Zafgen (ZFGN), ContraFect (CFRX) and Provectus Biopharmaceuticals (PVCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Coherus Biosciences (CHRS), Intercept Pharmaceuticals (ICPT), Verastem (VSTM), Agile Therapeutics (AGRX), Achaogen (AKAO), Fibrocell Science (FCSC), Lipocine (LPCN) and MEI Pharma (MEIP).

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DFFN stock can currently be purchased for approximately $1.45.

Diffusion Pharmaceuticals has a market capitalization of $6.80 million. The company earns $-18,370,000.00 in net income (profit) each year or ($6.08) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe.View Additional Information About Diffusion Pharmaceuticals.

The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com/.

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]